University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Francis Yao, MD

Francis Yao, MD

Associate Clinical Professor, Department of Medicine (Gastroenterology), UCSF

Selected Publications

  1. Goldaracena N, Mehta N, Scalera I, Sposito C, Atenafu EG, Yao FY, Muiesan P, Mazzaferro V, Sapisochin G. Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation. HPB (Oxford). 2018 Oct 31.
    View on PubMed
  2. Sherman CB, Behr S, Dodge JL, Roberts JP, Yao FY, Mehta N. Distinguishing Tumor from Bland Portal Vein Thrombus in Liver Transplant Candidates with Hepatocellular Carcinoma: The "A-VENA" Criteria. Liver Transpl. 2018 Sep 24.
    View on PubMed
  3. Lee DD, Samoylova M, Mehta N, Musto KR, Roberts JP, Yao FY, Harnois DM. mRECIST provides insight into tumor biology for patients with hepatocellular carcinoma awaiting liver transplantation. Liver Transpl. 2018 Sep 10.
    View on PubMed
  4. Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. Increasing Liver Transplant Waitlist Dropout for Hepatocellular Carcinoma with Widening Geographical Disparities: Implications for Organ Allocation. Liver Transpl. 2018 Aug 01.
    View on PubMed
  5. Samoylova ML, Mehta N, Roberts JP, Yao FY. Predictors of ultrasound failure to detect hepatocellular carcinoma. Liver Transpl. 2018 May 21.
    View on PubMed
  6. Mehta N, Yao FY. Living donor liver transplantation for hepatocellular carcinoma: To expand (beyond Milan) or downstage (to Milan)? Liver Transpl. 2018 Mar; 24(3):327-329.
    View on PubMed
  7. Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA. Direct-acting Antivirals Do Not Increase the Risk of Hepatocellular Carcinoma Recurrence after Local-Regional Therapy or Liver Transplant Waitlist Dropout. Hepatology. 2018 Feb 24.
    View on PubMed
  8. Giard JM, Mehta N, Dodge JL, Roberts JP, Yao FY. Alpha-fetoprotein Slope >7.5 ng/ml/month Predicts Micro-vascular Invasion and Tumor Recurrence after Liver Transplantation for Hepatocellular Carcinoma. Transplantation. 2018 Jan 17.
    View on PubMed
  9. Kotwani P, Saxena V, Dodge JL, Roberts J, Yao F, Hameed B. History of marijuana use does not affect outcomes on the liver transplant waitlist. Transplantation. 2018 Jan 10.
    View on PubMed
  10. Mehta N, Dodge JL, Roberts JP, Yao FY. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant. 2018 May; 18(5):1206-1213.
    View on PubMed
  11. Mehta N, Yao FY. Con: Treating hepatitis C virus With direct-acting antivirals: Fear not the perceived threat of hepatocellular carcinoma. Liver Transpl. 2017 Dec; 23(12):1596-1600.
    View on PubMed
  12. Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, Roberts JP, Yao FY. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study. Clin Gastroenterol Hepatol. 2017 Nov 23.
    View on PubMed
  13. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. Misdiagnosis of hepatocellular carcinoma in patients receiving no local-regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form. Clin Transplant. 2017 Nov; 31(11).
    View on PubMed
  14. Mehta N, Heimbach J, Lee D, Dodge JL, Harnois D, Burns J, Sanchez W, Roberts JP, Yao FY. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot". Transplantation. 2017 09; 101(9):2071-2078.
    View on PubMed
  15. Lewin SM, Mehta N, Kelley RK, Roberts JP, Yao FY, Brandman D. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma. Liver Transpl. 2017 08; 23(8):1015-1022.
    View on PubMed
  16. Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, Burns JM, Sanchez W, Greig PD, Grant DR, Roberts JP, Yao FY. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. JAMA Oncol. 2017 Apr 01; 3(4):493-500.
    View on PubMed
  17. Mehta N, Yao FY. Transarterial Radioembolization for Hepatocellular Carcinoma: Who, When… and Y(90)? Gastroenterology. 2016 12; 151(6):1062-1065.
    View on PubMed
  18. Mehta N, Yao FY. Reply. Liver Transpl. 2016 08; 22(8):1164-5.
    View on PubMed
  19. Sarkar M, Dodge JL, Roberts JP, Terrault N, Yao F, Mehta N.  Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant. Ann Hepatol. 2016 Jul-Aug; 15(4):545-9.
    View on PubMed
  20. Mehta N, Roberts JP, Yao FY. Lack of benefits of mammalian target of rapamycin inhibitor in patients transplanted for hepatocellular carcinoma: Is this the end of the story? Liver Transpl. 2016 05; 22(5):582-4.
    View on PubMed

Go to UCSF Profiles, powered by CTSI